Epipen
NDC Package 55045-3207-2

11-digit billing NDC: 55045320702

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Epipen is ® and EpiPen® Jr Auto-Injectors are indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. Marketed by Dispensing Solutions, Inc., this product is identified by NDC 55045-3207 and is authorized under FDA application NDA019430.

Identification & Billing

NDC Package Code
55045-3207-2
Package Description
1 CONTAINER in 1 CARTON / 1 SYRINGE, GLASS in 1 CONTAINER / .3 mL in 1 SYRINGE, GLASS
Product Code
11-Digit Billing Format
55045320702
RxNorm Crosswalk
  • RxCUI: 1870207 - EPINEPHrine (generic for EpiPen) 0.3 MG in 0.3 ML Auto-Injector
  • RxCUI: 1870207 - NDA019430 0.3 ML epinephrine 1 MG/ML Auto-Injector
  • RxCUI: 1870207 - epinephrine (generic for EpiPen) 0.3 MG per 0.3 ML Auto-Injector
  • RxCUI: 727347 - EpiPen 0.3 MG in 0.3 ML Auto-Injector
  • RxCUI: 727347 - NDA019430 0.3 ML epinephrine 1 MG/ML Auto-Injector [Epipen]

Clinical Specifications

Proprietary Name
Epipen
Dosage Form
-
Usage Information
EpiPen® and EpiPen® Jr Auto-Injectors are indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. EpiPen® and EpiPen® Jr Auto-Injectors are intended for immediate administration in patients, who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to patient body weight (see DOSAGE AND ADMINISTRATION section). Such reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria or angioedema. EpiPen® and EpiPen® Jr Auto-Injectors are intended for immediate self-administration as emergency supportive therapy only and are not a substitute for immediate medical care.

Regulatory & Marketing

Labeler Name
Dispensing Solutions, Inc.
FDA Application #
NDA019430
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
12-22-1987
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 55045-3207-2 identifies a specific commercial package of 1 container in 1 carton / 1 syringe, glass in 1 container / .3 ml in 1 syringe, glass of Epipen, labeled by Dispensing Solutions, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Dispensing Solutions, Inc. on December 22, 1987. The current certification is valid through December 31, 2017.

How is this Dispensing Solutions, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 55045320702. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
55045-3207-2
11-Digit CMS (5-4-2)
55045-3207-02

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.